Analysts predict that Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) will post earnings per share of ($0.50) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Aeglea Bio Therapeutics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.63). Aeglea Bio Therapeutics posted earnings per share of ($0.46) during the same quarter last year, which would indicate a negative year-over-year growth rate of 8.7%. The company is scheduled to report its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Aeglea Bio Therapeutics will report full year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($2.58) to ($1.81). For the next fiscal year, analysts forecast that the company will report earnings of ($1.90) per share, with EPS estimates ranging from ($2.24) to ($1.26). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow Aeglea Bio Therapeutics.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04).
A number of equities research analysts have recently issued reports on AGLE shares. HC Wainwright started coverage on shares of Aeglea Bio Therapeutics in a research note on Tuesday, May 21st. They issued a “buy” rating and a $20.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of Aeglea Bio Therapeutics in a research note on Thursday, March 21st. They issued an “overweight” rating and a $14.00 price target on the stock. Finally, ValuEngine downgraded shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 9th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Aeglea Bio Therapeutics has a consensus rating of “Hold” and an average price target of $14.33.
Shares of Aeglea Bio Therapeutics stock traded up $0.06 on Friday, reaching $6.33. The company had a trading volume of 2,140 shares, compared to its average volume of 162,538. The business has a 50 day simple moving average of $6.53. The stock has a market cap of $183.20 million, a price-to-earnings ratio of -2.98 and a beta of 0.96. Aeglea Bio Therapeutics has a 52-week low of $5.99 and a 52-week high of $11.37.
In other news, CEO Anthony G. Quinn acquired 6,218 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were bought at an average price of $6.65 per share, for a total transaction of $41,349.70. Following the completion of the purchase, the chief executive officer now directly owns 277,152 shares of the company’s stock, valued at approximately $1,843,060.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Anthony G. Quinn acquired 31,905 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were purchased at an average price of $6.16 per share, for a total transaction of $196,534.80. Following the purchase, the chief executive officer now directly owns 333,955 shares of the company’s stock, valued at $2,057,162.80. The disclosure for this purchase can be found here. Insiders have bought 92,177 shares of company stock worth $593,817 in the last quarter. Insiders own 12.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its position in Aeglea Bio Therapeutics by 38.4% during the first quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,967 shares during the period. Rhumbline Advisers grew its position in Aeglea Bio Therapeutics by 11.9% during the 1st quarter. Rhumbline Advisers now owns 24,130 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 2,559 shares during the last quarter. BNP Paribas Arbitrage SA bought a new stake in Aeglea Bio Therapeutics during the 1st quarter worth $32,000. Canada Pension Plan Investment Board bought a new stake in Aeglea Bio Therapeutics during the 4th quarter worth $37,000. Finally, Bank of New York Mellon Corp grew its position in Aeglea Bio Therapeutics by 11.6% during the 4th quarter. Bank of New York Mellon Corp now owns 49,470 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 5,150 shares during the last quarter. Institutional investors own 68.48% of the company’s stock.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Recommended Story: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.